Elinor Miller

2.2k total citations · 1 hit paper
19 papers, 1.7k citations indexed

About

Elinor Miller is a scholar working on Surgery, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Elinor Miller has authored 19 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 8 papers in Cancer Research and 7 papers in Economics and Econometrics. Recurrent topics in Elinor Miller's work include Lipoproteins and Cardiovascular Health (17 papers), Cancer, Lipids, and Metabolism (8 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). Elinor Miller is often cited by papers focused on Lipoproteins and Cardiovascular Health (17 papers), Cancer, Lipids, and Metabolism (8 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (6 papers). Elinor Miller collaborates with scholars based in United States, Norway and United Kingdom. Elinor Miller's co-authors include Evan A. Stein, Harold Bays, James M. McKenney, James W. Blasetto, Peter H. Jones, Michael H. Davidson, Valerie A. Cain, J. Ycas, Rohini Chitra and David Hassman and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and The American Journal of Medicine.

In The Last Decade

Elinor Miller

18 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

2003 1.1k citations Peter H. Jones, Michael H. Davidson et al. The American Journal of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elinor Miller United States	11	1.4k	599	567	352	282	19	1.7k
James W. Blasetto United States	12	1.5k 1.1×	635 1.1×	647 1.1×	397 1.1×	298 1.1×	22	1.8k
Irene Laurora United States	6	1.4k 1.0×	756 1.3×	579 1.0×	264 0.8×	372 1.3×	13	1.8k
Phillip D. Toth United States	11	1.3k 0.9×	382 0.6×	586 1.0×	254 0.7×	231 0.8×	25	1.8k
Joanne Palmisano United States	19	1.9k 1.3×	661 1.1×	805 1.4×	447 1.3×	652 2.3×	30	2.6k
David Neff United States	17	938 0.7×	299 0.5×	394 0.7×	233 0.7×	269 1.0×	39	1.4k
Amy O. Johnson‐Levonas United States	28	1.3k 0.9×	333 0.6×	801 1.4×	416 1.2×	344 1.2×	89	2.4k
José Luis Zamorano Spain	9	1.6k 1.2×	595 1.0×	781 1.4×	302 0.9×	787 2.8×	16	2.4k
Lorenzo Melani Italy	19	1.7k 1.2×	530 0.9×	554 1.0×	665 1.9×	448 1.6×	28	2.3k
Eli M. Roth United States	24	2.1k 1.5×	781 1.3×	587 1.0×	315 0.9×	586 2.1×	60	2.7k
Christine McCrary Sisk United States	21	897 0.6×	181 0.3×	588 1.0×	205 0.6×	287 1.0×	54	1.4k

Countries citing papers authored by Elinor Miller

Since Specialization

Citations

This map shows the geographic impact of Elinor Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elinor Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elinor Miller more than expected).

Fields of papers citing papers by Elinor Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elinor Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elinor Miller. The network helps show where Elinor Miller may publish in the future.

Co-authorship network of co-authors of Elinor Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Elinor Miller. A scholar is included among the top collaborators of Elinor Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elinor Miller. Elinor Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Braamskamp, Marjet J.A.M., Gisle Langslet, David Cassiman, et al.. (2018). Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children with Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Yearbook of pediatric endocrinology. 5 indexed citations

Braamskamp, Marjet J.A.M., Gisle Langslet, Brian W. McCrindle, et al.. (2017). Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. Circulation. 136(4). 359–366. 74 indexed citations

Braamskamp, Marjet J.A.M., Gisle Langslet, Brian W. McCrindle, et al.. (2015). Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study. Journal of clinical lipidology. 9(6). 741–750. 33 indexed citations

Langslet, Gisle, Marjet J.A.M. Braamskamp, Brian W. McCrindle, et al.. (2014). EFFECT OF ROSUVASTATIN THERAPY ON ARTERIAL WALL CHANGES IN CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY. Journal of the American College of Cardiology. 63(12). A1379–A1379. 2 indexed citations

Langslet, Gisle, Marjet J.A.M. Braamskamp, Brian W. McCrindle, et al.. (2014). EFFICACY AND SAFETY OF ROSUVASTATIN THERAPY FOR CHILDREN AND ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE CHARON STUDY. Journal of the American College of Cardiology. 63(12). A1288–A1288.

Braamskamp, Marjet J.A.M., Gisle Langslet, Brian W. McCrindle, et al.. (2014). Efficacy and safety of rosuvastatin in children aged 6–17 years with familial hypercholesterolemia: Findings from the charon study. Atherosclerosis. 235(2). e34–e34. 1 indexed citations

Braamskamp, Marjet J.A.M., Gisle Langslet, Brian W. McCrindle, et al.. (2014). Effect of rosuvastatin therapy on carotid intima media thickness in children with familial hypercholesterolemia: Findings from the charon study. Atherosclerosis. 235(2). e18–e19. 5 indexed citations

Pitt, Bertram, Joseph Loscalzo, John T. Monyak, Elinor Miller, & Joel S. Raichlen. (2012). Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). The American Journal of Cardiology. 109(9). 1239–1246. 50 indexed citations

Ferdinand, Keith C., et al.. (2008). Relationship of Ethnic Origin, Gender, and Age to Blood Creatine Kinase Levels. The American Journal of Medicine. 122(1). 73–78. 87 indexed citations

10.

Blom, Dirk, A. David Marais, Kjetil Retterstøl, et al.. (2008). Rosuvastatin reduces non–high-density lipoprotein cholesterol and lipoprotein remnants in patients with dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). Journal of clinical lipidology. 2(6). 418–425. 7 indexed citations

11.

Shepherd, James, Donald G. Vidt, Elinor Miller, Susan S. Harris, & James W. Blasetto. (2007). Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program. Cardiology. 107(4). 433–443. 66 indexed citations

12.

Insull, William, Jalal K. Ghali, David Hassman, et al.. (2007). Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR Trial. Mayo Clinic Proceedings. 82(5). 543–550. 32 indexed citations

13.

Ballantyne, Christie M., Elinor Miller, & Rohini Chitra. (2004). Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. Clinical Therapeutics. 26(11). 1855–1864. 24 indexed citations

14.

Stein, Evan A., et al.. (2003). Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. The American Journal of Cardiology. 92(11). 1287–1293. 89 indexed citations

15.

Jones, Peter H., Michael H. Davidson, Evan A. Stein, et al.. (2003). Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial). The American Journal of Cardiology. 92(2). 152–160. 1092 indexed citations breakdown →

16.

Brown, W. Virgil, Harold Bays, David Hassman, et al.. (2002). Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. American Heart Journal. 144(6). 1036–1043. 136 indexed citations

17.

Hatsukami, Thomas S., et al.. (2001). Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenois. Atherosclerosis Supplements. 2(2). 47–48. 8 indexed citations

18.

Stein, Evan A., et al.. (2001). Rosuvastatin (20, 40 and 80 MG) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 MG) in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis Supplements. 2(2). 90–91. 21 indexed citations

19.

Chrysant, Steven G. & Elinor Miller. (1994). Effects of atenolol and diltiazem‐SR on exercise and pressure load in hypertensive patients. Clinical Cardiology. 17(12). 670–674. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact